| Schedule of Segment Financial Performance |
Summary
segment financial performance measures evaluated by the CODM as of June 30, 2026 and December 31, 2025 and for the three and six months
ended June 30, 2026 and 2025:
Schedule of Segment Financial Performance
| | |
June 30, 2026 | | |
December 31, 2025 | |
| | |
Segment Assets | |
| | |
June 30, 2026 | | |
December 31, 2025 | |
| Digital asset treasury segment | |
$ | 563,869,389 | | |
$ | 513,964,900 | |
| Clinical stage bio-technology segment – continuing operations | |
| - | | |
| - | |
| Clinical stage bio-technology segment – held for sale | |
| 700,997 | | |
| 5,181,535 | |
| Total assets | |
$ | 564,570,386 | | |
$ | 519,146,435 | |
Digital
asset treasury segment
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
For the three months ended June 30, | | |
For the six months ended June 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| Loss from operations | |
$ | (1,202,154 | ) | |
$ | - | | |
$ | (36,423,335 | ) | |
$ | - | |
| Other income (expense) (a) | |
| 311,848 | | |
| - | | |
| 630,026 | | |
| - | |
| Unrealized loss on digital assets holdings | |
| (23,735,950 | ) | |
| - | | |
| (38,749,254 | ) | |
| - | |
Clinical
stage bio-technology segment
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
For the three months ended June 30, | | |
For the six months ended June 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| Loss from operations – continuing operations | |
$ | - | | |
$ | (1,428,594 | ) | |
$ | - | | |
$ | (3,472,642 | ) |
| Loss from operations – discontinued operations | |
| (1,300,745 | ) | |
| (422,566 | ) | |
| (2,947,875 | ) | |
| (925,187 | ) |
| Loss from operations | |
| (1,300,745 | ) | |
| (422,566 | ) | |
| (2,947,875 | ) | |
| (925,187 | ) |
| Other income (expense) (a) | |
| - | | |
| (3,993 | ) | |
| - | | |
| 972 | |
| |
(a) |
Other
income (expense) consists of interest income and interest expense. |
The
following table is a reconciliation of segment total loss before income taxes to our consolidated total loss before income taxes.
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
For the three months ended June 30, | | |
For the six months ended June 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| Digital asset treasury segment total loss before income taxes | |
$ | (24,626,256 | ) | |
$ | - | | |
$ | (74,542,563 | ) | |
$ | - | |
| Clinical stage bio-technology segment total loss before income taxes – continuing operations | |
| - | | |
| (1,432,587 | ) | |
| | | |
| (3,471,670 | ) |
| Clinical stage bio-technology segment total loss before income taxes – discontinued operations | |
| (1,300,745 | ) | |
| (422,566 | ) | |
| (2,947,875 | ) | |
| (925,187 | ) |
| Consolidated total loss before income taxes | |
$ | (25,927,001 | ) | |
$ | (1,855,153 | ) | |
$ | (77,490,438 | ) | |
$ | (4,396,857 | ) |
|